Celldex tanks as Rintega fails in Phase III brain cancer trial

8 March 2016

Shares of US immunotherapy specialists Celldex Therapeutics (Nasdaq: CLDX) slumped as much as 59% to $3.37 in pre-market trading on Monday, after the company said that its pivotal late-stage trial with its brain cancer drug Rintega (rindopepimut) had failed.

Celldex announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a pre-planned interim analysis, that continuation of the Phase III ACT IV study of Rintega in patients with newly-diagnosed EGFRvIII-positive glioblastoma will not reach statistical significance for overall survival in patients with minimal residual disease, the primary endpoint of the study, as both the Rintega arm and the control arm are performing on par with each other.

Difficulties of developing cancer vaccine

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK